Camden National Bank decreased its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,298 shares of the company’s stock after selling 1,222 shares during the quarter. Merck & accounts for approximately 2.8% of Camden National Bank’s portfolio, making the stock its 12th largest holding. Camden National Bank’s holdings in Merck & were worth $9,248,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Stelac Advisory Services LLC acquired a new stake in Merck & in the 2nd quarter valued at $104,000. Perennial Advisors LLC grew its stake in Merck & by 10.7% in the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after acquiring an additional 157 shares during the period. Cascade Investment Advisors Inc. grew its stake in Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the period. Vigilant Capital Management LLC grew its stake in Merck & by 16.7% in the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after acquiring an additional 250 shares during the period. Finally, Solaris Asset Management LLC grew its stake in Merck & by 6.3% in the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the period. 72.86% of the stock is currently owned by institutional investors and hedge funds.

Merck & Company, Inc. (NYSE:MRK) opened at $56.06 on Friday. Merck & Company, Inc. has a fifty-two week low of $54.41 and a fifty-two week high of $66.80. The company has a current ratio of 1.50, a quick ratio of 1.21 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $153,333.30, a price-to-earnings ratio of 14.41, a PEG ratio of 2.41 and a beta of 0.78.

Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The business had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. During the same quarter in the previous year, the firm earned $1.07 EPS. The company’s quarterly revenue was down 2.0% compared to the same quarter last year. research analysts expect that Merck & Company, Inc. will post 3.95 earnings per share for the current year.

WARNING: “Camden National Bank Has $9.25 Million Stake in Merck & Company, Inc. (MRK)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/camden-national-bank-has-9-25-million-stake-in-merck-company-inc-mrk/1679561.html.

A number of equities research analysts recently issued reports on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $73.00 price target (down previously from $74.00) on shares of Merck & in a research note on Monday, July 24th. BidaskClub cut shares of Merck & from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Morgan Stanley cut shares of Merck & from an “overweight” rating to an “equal weight” rating and set a $56.00 price target on the stock. in a research note on Monday, October 30th. UBS AG dropped their price target on shares of Merck & from $72.00 to $67.00 and set a “buy” rating on the stock in a research note on Monday, October 30th. Finally, Jefferies Group LLC cut shares of Merck & from a “hold” rating to an “underperform” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. Merck & presently has an average rating of “Hold” and an average target price of $67.07.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.